首頁/SYK

公开研究页

行情来自市场数据接口；下方公司研究基于已核验公开来源，但不等同于实时、个性化的 AI 投资结论。

去工作台分析 SYK
SYKNYSE/health care

Stryker Corporation

$331.45上涨+1,67 (+0,51%)
研究复核截至: 2026年7月12日 上午12:00 [UTC]
研究概览近 3 个月价格投资论点关键催化剂最新财报研究近期新闻数据与研究来源

研究概览

Stryker Corporation operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Ouverture
330,18
Haut
335,96
Bas
329,10
Capitalisation
127,06 Md
Ratio C/B
38.36
Plus haut sur 52 semaines
--
Dividende
1.070%
Dividende trimestriel
--

近 3 个月价格

這裡展示近 3 個月價格走勢，幫助使用者先理解短期結構，再決定是否進入完整研究工作台。

投资论点

基础情景
Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption. The base case remains conditional on supply and manufacturing staying manageable.
多头情景
Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption. Healthy elective procedure volumes can sustain demand across hips, knees, trauma and surgical equipment. New implants, neurovascular tools and operating-room technologies can extend share gains.
空头情景
Component shortages, quality issues or sterilization constraints could disrupt high-demand product availability. Budget pressure can delay purchases of robots, beds and other capital equipment. Frequent portfolio additions can raise integration, valuation and management-attention risk.
论点失效条件
Reassess the thesis if component shortages, quality issues or sterilization constraints could disrupt high-demand product availability.

关键催化剂

  • Mako installed base

    Robotic placements can pull through implants, disposables and service revenue while deepening surgeon adoption.

  • Procedure growth

    Healthy elective procedure volumes can sustain demand across hips, knees, trauma and surgical equipment.

  • Product innovation

    New implants, neurovascular tools and operating-room technologies can extend share gains.

主要风险

  • Supply and manufacturing

    Component shortages, quality issues or sterilization constraints could disrupt high-demand product availability.

  • Hospital capital budgets

    Budget pressure can delay purchases of robots, beds and other capital equipment.

  • Acquisition execution

    Frequent portfolio additions can raise integration, valuation and management-attention risk.

最新财报研究

Q1 2026

Stryker's first-quarter 2026 results reflected continued demand across MedSurg, Neurotechnology and Orthopaedics, supported by procedure volumes, capital equipment and product innovation.

估值解读

  • The installed-base model supports premium quality when robotic placements translate into recurring implant and service pull-through.
  • Procedure resilience should be assessed alongside hospital capital cycles and ongoing acquisition requirements.

同行比较入口

ABTBSXISRG

近期新闻

Zacks · il y a 3 jours

ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?

Simply Wall St. · il y a 4 jours

Stryker (SYK) Stock Loses Russell Growth Slots As Active Investors Step In

Barchart · il y a 4 jours

Stryker's Quarterly Earnings Preview: What You Need to Know

Insider Monkey · il y a 4 jours

Mixed Drivers Fuel Optimism in Stryker Corporation’s (SYK) Performance

Trefis · il y a 5 jours

The Wide Chasm Priced Into Boston Scientific Stock

Trefis · il y a 5 jours

Just How Much Risk Is Built Into ISRG Stock?

数据与研究来源

研究更新: 2026年7月12日 上午12:00 [UTC]
3 个已核验来源
First Quarter 2026 Operating ResultsStryker Corporation · earnings已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/4/30 上午12:00:00

查看原始来源
Stryker Corporation Investor RelationsStryker Corporation · company已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

查看原始来源
Stryker SEC filings and company factsU.S. Securities and Exchange Commission · filing已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/4/30 上午12:00:00

查看原始来源

在工作台中继续研究

保留 SYK，运行多智能体分析并持续跟踪论点变化。

免费分析 SYK

探索完整研究體系

每個階段職責明確，並為下一階段留下可追溯的輸出。

研究方法論閱讀市場報告瀏覽股票

继续深挖这只股票

市場分析 Agent

負責先判断价格結構、趋势强弱與交易節奏有没有支持 thesis。

基本面分析 Agent

負責判断公司的业务质量、盈利結構與财务健康度。

新闻分析 Agent

追踪最近发生了什么，以及這些事件是否真的改变 thesis。

風險经理 Agent

負責在風險辩論后给出最终風險等級和执行邊界。